BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

283 related articles for article (PubMed ID: 28689240)

  • 1. suPAR and chronic kidney disease-a podocyte story.
    Zeier M; Reiser J
    Pflugers Arch; 2017 Aug; 469(7-8):1017-1020. PubMed ID: 28689240
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Recurrent Primary Focal Segmental Glomerulosclerosis Managed With Intensified Plasma Exchange and Concomitant Monitoring of Soluble Urokinase-Type Plasminogen Activator Receptor-Mediated Podocyte β3-integrin Activation.
    Staeck O; Slowinski T; Lieker I; Wu K; Rudolph B; Schmidt D; Brakemeier S; Neumayer HH; Wei C; Reiser J; Budde K; Halleck F; Khadzhynov D
    Transplantation; 2015 Dec; 99(12):2593-7. PubMed ID: 26371597
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Changes in podocyte TRPC channels evoked by plasma and sera from patients with recurrent FSGS and by putative glomerular permeability factors.
    Kim EY; Roshanravan H; Dryer SE
    Biochim Biophys Acta Mol Basis Dis; 2017 Sep; 1863(9):2342-2354. PubMed ID: 28629718
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Soluble urokinase receptor and focal segmental glomerulosclerosis.
    Reiser J; Wei C; Tumlin J
    Curr Opin Nephrol Hypertens; 2012 Jul; 21(4):428-32. PubMed ID: 22569341
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Bone marrow-derived immature myeloid cells are a main source of circulating suPAR contributing to proteinuric kidney disease.
    Hahm E; Wei C; Fernandez I; Li J; Tardi NJ; Tracy M; Wadhwani S; Cao Y; Peev V; Zloza A; Lusciks J; Hayek SS; O'Connor C; Bitzer M; Gupta V; Sever S; Sykes DB; Scadden DT; Reiser J
    Nat Med; 2017 Jan; 23(1):100-106. PubMed ID: 27941791
    [TBL] [Abstract][Full Text] [Related]  

  • 6. RAGE and αVβ3-integrin are essential for suPAR signaling in podocytes.
    Kim EY; Dryer SE
    Biochim Biophys Acta Mol Basis Dis; 2021 Oct; 1867(10):166186. PubMed ID: 34166766
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Soluble Urokinase Receptors in Focal Segmental Glomerulosclerosis: A Review on the Scientific Point of View.
    Kronbichler A; Saleem MA; Meijers B; Shin JI
    J Immunol Res; 2016; 2016():2068691. PubMed ID: 27504461
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A tripartite complex of suPAR, APOL1 risk variants and α
    Hayek SS; Koh KH; Grams ME; Wei C; Ko YA; Li J; Samelko B; Lee H; Dande RR; Lee HW; Hahm E; Peev V; Tracy M; Tardi NJ; Gupta V; Altintas MM; Garborcauskas G; Stojanovic N; Winkler CA; Lipkowitz MS; Tin A; Inker LA; Levey AS; Zeier M; Freedman BI; Kopp JB; Skorecki K; Coresh J; Quyyumi AA; Sever S; Reiser J
    Nat Med; 2017 Aug; 23(8):945-953. PubMed ID: 28650456
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Circulating urokinase receptor as a cause of focal segmental glomerulosclerosis.
    Wei C; El Hindi S; Li J; Fornoni A; Goes N; Sageshima J; Maiguel D; Karumanchi SA; Yap HK; Saleem M; Zhang Q; Nikolic B; Chaudhuri A; Daftarian P; Salido E; Torres A; Salifu M; Sarwal MM; Schaefer F; Morath C; Schwenger V; Zeier M; Gupta V; Roth D; Rastaldi MP; Burke G; Ruiz P; Reiser J
    Nat Med; 2011 Jul; 17(8):952-60. PubMed ID: 21804539
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Urinary soluble urokinase receptor levels are elevated and pathogenic in patients with primary focal segmental glomerulosclerosis.
    Huang J; Liu G; Zhang YM; Cui Z; Wang F; Liu XJ; Chu R; Zhao MH
    BMC Med; 2014 May; 12():81. PubMed ID: 24884842
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Full-length soluble urokinase plasminogen activator receptor down-modulates nephrin expression in podocytes.
    Alfano M; Cinque P; Giusti G; Proietti S; Nebuloni M; Danese S; D'Alessio S; Genua M; Portale F; Lo Porto M; Singhal PC; Rastaldi MP; Saleem MA; Mavilio D; Mikulak J
    Sci Rep; 2015 Sep; 5():13647. PubMed ID: 26380915
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Podocyte effacement closely links to suPAR levels at time of posttransplantation focal segmental glomerulosclerosis occurrence and improves with therapy.
    Alachkar N; Wei C; Arend LJ; Jackson AM; Racusen LC; Fornoni A; Burke G; Rabb H; Kakkad K; Reiser J; Estrella MM
    Transplantation; 2013 Oct; 96(7):649-56. PubMed ID: 23842190
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Serum suPAR in patients with FSGS: trash or treasure?
    Maas RJ; Deegens JK; Wetzels JF
    Pediatr Nephrol; 2013 Jul; 28(7):1041-8. PubMed ID: 23515666
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Extrarenal determinants of kidney filter function.
    Hahm E; Peev V; Reiser J
    Cell Tissue Res; 2017 Jul; 369(1):211-216. PubMed ID: 28560690
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Management of severe recurrent focal segmental glomerulosclerosis through circulating soluble urokinase receptor modification.
    Morath C; Wei C; Macher-Goeppinger S; Schwenger V; Zeier M; Reiser J
    Am J Ther; 2013; 20(2):226-9. PubMed ID: 23466622
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Monitoring suPAR levels in post-kidney transplant focal segmental glomerulosclerosis treated with therapeutic plasma exchange and rituximab.
    Alachkar N; Li J; Matar D; Vujjini V; Alasfar S; Tracy M; Reiser J; Wei C
    BMC Nephrol; 2018 Dec; 19(1):361. PubMed ID: 30558559
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Circulating permeability factor suPAR: from concept to discovery to clinic.
    Reiser J
    Trans Am Clin Climatol Assoc; 2013; 124():133-8. PubMed ID: 23874017
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Diagnostic and Prognostic Value of Soluble Urokinase-type Plasminogen Activator Receptor (suPAR) in Focal Segmental Glomerulosclerosis and Impact of Detection Method.
    Winnicki W; Sunder-Plassmann G; Sengölge G; Handisurya A; Herkner H; Kornauth C; Bielesz B; Wagner L; Kikić Ž; Pajenda S; Reiter T; Schairer B; Schmidt A
    Sci Rep; 2019 Sep; 9(1):13783. PubMed ID: 31551522
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Primary and Recurrent Focal Segmental Glomerulosclerosis Closely Link to Serum Soluble Urokinase-type Plasminogen Activator Receptor Levels.
    Jin J; Li YW; He Q
    Transplant Proc; 2015; 47(6):1760-5. PubMed ID: 26293047
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Sphingomyelinase-like phosphodiesterase 3b expression levels determine podocyte injury phenotypes in glomerular disease.
    Yoo TH; Pedigo CE; Guzman J; Correa-Medina M; Wei C; Villarreal R; Mitrofanova A; Leclercq F; Faul C; Li J; Kretzler M; Nelson RG; Lehto M; Forsblom C; Groop PH; Reiser J; Burke GW; Fornoni A; Merscher S
    J Am Soc Nephrol; 2015 Jan; 26(1):133-47. PubMed ID: 24925721
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.